Gaudium IVF IPO GMP: Latest Grey Market Premium, Subscription & Listing Outlook

The Gaudium IVF IPO GMP is currently around ₹8–₹10 per share, indicating a potential listing gain of nearly 10–13% over the upper price band of ₹79.

If you’re tracking this IPO for listing gains or long-term investment, here’s a complete breakdown of the latest GMP, subscription status, IPO details, risks, and listing outlook – explained in simple terms.

Gaudium IVF IPO: Key Details at a Glance

IPO Detail	Information
Company Name	Gaudium IVF & Women Health Ltd.
IPO Type	SME IPO
Price Band	₹75 – ₹79 per share
Face Value	₹10 per share
Lot Size	1,600 shares
Minimum Investment (Retail)	₹1,26,400 (1 lot at ₹79)
Issue Size	Approx. ₹48–50 crore
IPO Open Date	February 2026
IPO Close Date	February 2026
Listing Platform	NSE SME

Always confirm final dates and numbers from NSE or the official RHP before investing.

---

Gaudium IVF IPO GMP Today

Latest Grey Market Premium (GMP)

Date	GMP (₹)	Estimated Listing Price (₹)	Expected Gain (%)
20 Feb 2026	₹8.5	₹87.5	~10.8%
19 Feb 2026	₹10	₹89	~12.7%
Earlier Peak	₹15	₹94	~18.9%

How Listing Price Is Estimated

Upper Price Band (₹79) + GMP (₹8.5) = ₹87.5 Estimated Listing

⚠️ Important: GMP is unofficial and can change daily. It reflects market sentiment – not a guaranteed listing price.

What Does This GMP Indicate?

A positive GMP usually suggests:

• Strong investor interest
• Possible listing premium
• Healthy grey market demand

However, SME IPOs can be volatile. GMP can drop sharply before listing day.

Think of GMP as a “temperature check” – not a final result.

Gaudium IVF IPO Subscription Status

(Indicative category-wise interest)

Investor Category	Subscription (Approx.)
Retail Investors (RII)	3–5x
HNI/NII	4–6x
QIB	Limited (SME IPO structure)
Overall Subscription	4–6x (Approx.)

Higher subscription generally means tougher allotment chances and stronger listing expectations.

About Gaudium IVF & Women Health Ltd.

Gaudium IVF operates in the fertility and women’s healthcare segment, offering:

• IVF treatments
• Fertility preservation
• Women’s health services
• Advanced reproductive technologies

India’s fertility treatment market is growing due to:

• Rising infertility awareness
• Delayed parenthood trends
• Urban lifestyle changes
• Better medical technology

This sector has long-term growth potential, but it is also highly competitive.

Should You Apply for Listing Gains?

If your goal is short-term listing gains:

• Positive GMP supports listing premium expectations
• Moderate subscription adds demand strength
• Healthcare sector has stable sentiment

But remember:

• SME stocks can hit upper or lower circuits quickly
• Liquidity can be limited
• Volatility is higher than mainboard IPOs

Risks to Consider

Before investing, understand the risks:

• SME IPO liquidity risk
• Dependence on fertility treatment demand
• Regulatory changes in healthcare
• Competition from established IVF chains

Never invest based only on GMP hype.

Listing Day Strategy

Here are three practical approaches investors use:

Conservative Strategy

Sell on listing if gain >10–15%.

Balanced Strategy

Sell 50% on listing, hold 50% long term.

Long-Term Strategy

Hold if company shows strong revenue growth and expansion plans.

Choose based on your risk appetite.

Final Verdict: Gaudium IVF IPO GMP Outlook

The Gaudium IVF IPO GMP of ₹8–₹10 suggests a possible 10–13% listing gain, but this is not guaranteed.

If subscription remains strong and market sentiment stays positive, listing could be stable to positive. However, SME IPOs carry higher volatility.

Do your own research. Align your decision with your financial goals – not just grey market trends.

Frequently Asked Questions (FAQs)

Key Takeaways

• GMP: ₹8–₹10 (approx.)
• Expected listing gain: 10–13%
• SME IPO – higher risk, higher volatility
• Don’t rely only on GMP